Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter January 11, 2020

Intravenous insulin therapy in diabetes mellitus with hyperglycemic crisis and intercurrent illness

  • Budi Suprapti EMAIL logo , Fairuza Syarfina , Chrismawan Ardianto and Cahyo Wibisono



Hyperglycemic crisis is one of the complications of diabetes mellitus, which is common in hospitalized diabetic patient with intercurrent illness, requiring immediate action to control blood glucose. As an effort to attain rapid, gradually and more definite blood glucose, insulin is given intravenously. This study aimed to explore the patterns of blood glucose in hyperglycemic crisis and intercurrent illness, precipitating conditions, insulin regimen and blood glucose (BG) level results.


It was a cross-sectional study conducted on type 2 diabetic patients. The inclusion criteria were as follows: hospitalized in the general/internal medicine ward with or without any complication or comorbidity receiving intravenous insulin therapy; have pre- and post-BG data after insulin intervention.


In 3 months of the study period, 22 patients fulfilled the inclusion criteria with 28 cases of intravenous insulin therapy, and 1 patient could get more than one intervention. The major condition toward a hyperglycemic crisis condition was infection. The patient’s BG before interventions was 243 mg/dL to more than 600 mg/dL. The dosage of insulin varied from 4 to 10 units per hour, intravenously with a frequency of 1–4 times. The dosage consideration was not only based on BG levels but also on the patient’s condition. The reduction in BG level varied greatly between 0.2 and 28.1 mg/dL per unit of insulin. The BG level of three patients did not decrease. On the other hand, one patient experienced mild hypoglycemia.


Infection conditions were the most common factor for the hyperglycemia crisis. Moreover, intravenous insulin dosing was done individually, and there was a large variation in the results of the decrease in BG levels.

  1. Research funding: None declared.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Informed consent was obtained from all individuals included in this study.

  5. Ethical approval: Research involving human subjects complied with all relevant national regulations, institutional policies and is in accordance with the tenets of the Helsinki Declaration (as revised in 2013), and has been approved by the authors’ institutional review board (079/KEH/2017).


[1] Triplitt CL, Repas T, Alvarez CA. Diabetes mellitus. In: Dipiro JT, editor. Pharmacotherapy: a pathophysiologic approach, 9th ed. New York: McGraw Hill Education, 2014:1143–252.Search in Google Scholar

[2] McDonnell ME, Ummpierrez G. Insulin therapy for the management of hyperglycemia in hospitalized patients. Endocrinol Metab Clin North Am 2012;41:175–201.10.1016/j.ecl.2012.01.001Search in Google Scholar

[3] Casqueiro J, Casquerio J, Alves C. Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab 2015;16:S27–36.10.4103/2230-8210.94253Search in Google Scholar

[4] Goguen J, Gilbert J. Hyperglycemic emergencies in adults, 2018 Clinical Practice Guideline. Can J Diabetes 2018;42:S109–14.10.1016/j.jcjd.2017.10.013Search in Google Scholar

[5] World Health Organization. Diabetes World Health Organization. Geneva: World Health Organization, 2016.Search in Google Scholar

[6] Suprapti B, Widyasari N, Rahmadi M, WibisonoIndonesian C. Review of insulin therapy in type 2 diabetes mellitus ambulatory patients. J Pharm 2017;28:221–31.10.14499/indonesianjpharm28iss4pp221Search in Google Scholar

[7] Kroon LA, Assemi M, Carlisle BA. Diabetes Mellitus. In: Koda-Kimble MA, editor. Applied therapeutics: the clinical use of drugs, 9th ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins, 2009:50-5–50-43.Search in Google Scholar

[8] Breuer T, Meier JJ. Inpatient treatment of type 2 diabetes. Dtsch Arztebl Int 2012;109:466–74.10.3238/arztebl.2012.0466Search in Google Scholar

[9] Chen H, Zhang Y, Wu D, Gong C, Pan Q, Dong X, et al. Comorbidity in adult patients hospitalized with type 2 diabetes in northeast China: an analysis of hospital discharge data from 2002 to 2013. Biomed Res Intl 2016;2016:1–10.10.1155/2016/1671965Search in Google Scholar

[10] Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet 2009;373:1798–807.10.1016/S0140-6736(09)60553-5Search in Google Scholar

[11] Powers AC. Obesity, diabetes mellitus and metabolic syndrome. In: Kasper DL, editor. Harrison’s principles of internal medicine, 19th ed. New York, USA: McGraw Hill Companies Inc., 2015:2402, 2420–1, 2426, 2429.Search in Google Scholar

[12] Suprapti B, Pranoto A, Avrilena Mp. A, Samirah S, Nilamsari WP. The effect of regular human insulin and glulisine insulin on blood glucosa concentration in diabetic nephropathy patients with hyperglycemia. Int J Pharm Teach Pract 2013;4:492–8.Search in Google Scholar

[13] Hellquist K, Bradley R, Grambart S, Kapustin J, Loch J. Collaborative practice benefits patients: an examination of interprofessional approaches to diabetes care. Integr Med 2012;11:43–8.10.7772/2159-1253.1017Search in Google Scholar

[14] Johnson JM, Carragher R. Interprofessional collaboration and the care and management of type 2 diabetic patients in the Middle East: a systematic review. J Interprofession Care 2018;32:621–8.10.1080/13561820.2018.1471052Search in Google Scholar PubMed

Received: 2019-11-08
Accepted: 2019-11-28
Published Online: 2020-01-11

© 2019 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 2.6.2023 from
Scroll to top button